Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-DOTA-RW03
- Development stage
- Preclinical
- Lead developer
- Lunenfeld-Tanenbaum Research Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[177Lu]Lu-DOTA-RW03 is a therapeutic radiopharmaceutical consisting of a fully humanized monoclonal antibody, RW03, which targets CD133 (prominin-1), conjugated to the beta-emitting radioisotope lutetium-177 (177Lu) via the DOTA chelator. CD133 is a glycoprotein frequently expressed on cancer stem cells in various solid tumors, including glioblastoma and colorectal cancer. By binding specifically to CD133-positive cells, the agent delivers localized ionizing radiation, resulting in DNA damage and apoptosis. In preclinical studies presented at AACR 2026, Imaging Mass Cytometry (IMC) was used to assess the single-cell biodistribution and functional response of the drug, demonstrating its ability to target CD133+ tumor regions and induce therapeutic effects.
- Other names
- 177Lu-DOTA-RW03Lu-177-DOTA-RW03Lu177-DOTA-RW03Lu 177-DOTA-RW03
02
Targets
CD133 (CD133 antigen)
Beyond the preview
Go deeper on [177Lu]Lu-DOTA-RW03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-DOTA-RW03.